Business Context and Reporting Period
This Form 8-K is a current report filed by Coeptis Therapeutics Holdings, Inc. (not Z Squared Inc.) on December 26, 2024. The registrant is a Delaware corporation with its principal executive offices in Wexford, Pennsylvania. The report details corporate actions taken on December 26 and 27, 2024, regarding its capital structure.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial statement line items.
Material Changes
- Reverse Stock Split: The Company announced a 1-for-20 reverse stock split of its common stock, effective after market close on December 30, 2024.
- Trading Resumption: Post-split trading on the Nasdaq Capital Market is scheduled to begin at market open on December 31, 2024.
- CUSIP Change: The CUSIP number for the common stock will change to 19207A 207.
- Corporate Charter Amendment: A Certificate of Amendment to the Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State on December 26, 2024.
- Fractional Shares: No fractional shares will be issued; holders entitled to fractions will receive one whole share.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary on operational performance. The primary risk disclosed relates to the mechanics of the reverse split, specifically the treatment of fractional shares and the adjustment of outstanding equity awards, warrants, and exercise prices. The Board of Directors and majority shareholders authorized the split within a range of 1-for-3 to 1-for-40, selecting the 1-for-20 ratio.
Investor Verification Checklist
- Verify the effective date of the 1-for-20 reverse split (December 30, 2024) and the new trading start date (December 31, 2024).
- Confirm the new CUSIP number (19207A 207) for trading and settlement purposes.
- Review the treatment of fractional shares (rounding up to one whole share) and its impact on total share count.
- Check for proportionate adjustments to outstanding warrants (COEPW) and equity incentive plans.
- Confirm that the par value of the common stock remains unchanged at $0.0001.